Cost of illness and economic burden of chronic lymphocytic leukemia
Open Access
- 1 January 2013
- journal article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 32
Abstract
Chronic lymphocytic leukemia (CLL) is a slowly progressing but fatal disease that imposes a high economic burden on sickness funds and society. The objective of this study was to analyze and compare the direct and indirect costs of CLL in Germany from the perspective of the sickness funds and society and analyze the burden of the disease.Keywords
This publication has 24 references indexed in Scilit:
- Cost-of-Illness StudiesPharmacoEconomics, 2011
- Genetic Susceptibility Variants for Chronic Lymphocytic LeukemiaCancer Epidemiology, Biomarkers & Prevention, 2010
- Uncertainty Assessment of Input Parameters for Economic Evaluation: Gauss’s Error Propagation, an Alternative to Established MethodsMedical Decision Making, 2009
- The risk of upcoding in casemix systems: A comparative studyHealth Policy, 2007
- Cost of illness of malignant lymphoma in GermanyEuropean Journal of Cancer Care, 2006
- Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation - ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG)Das Gesundheitswesen, 2005
- Chronic Lymphocytic Leukemia: Economic Burden and Quality of LifeAmerican Journal of Therapeutics, 2005
- Ageing and health‐care expenditure: the red herring argument revisitedHealth Economics, 2004
- Likelihood Ratio Tests for Model Selection and Non-Nested HypothesesEconometrica, 1989
- Bootstrap Methods: Another Look at the JackknifeThe Annals of Statistics, 1979